Abstract
The neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) causes a parkinsonian syndrome in humans and primates after selective uptake of its metabolite, MPP+, into dopaminergic neurons. We sought to determine the major pathway of MPTP toxicity from among several apoptotic pathways. In this study, we established in vivo models of the inhibition of caspase cascade using adeno-asociated virus (AAV) vectors. We showed persistent high levels of focal Apaf-1 CARD or caspase-1 C285G mutant expression were available for further in vivo studies and for possible anti-apoptotic gene therapy in patients with Parkinson’s disease.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Y. Mizuno, S. Ikebe, S. Hattori, Y. Nakagawa-Hattori, H. Mochizuki et al. Role of mitochondria in the etiology and pathogenesis of Parkinson’s disease. Biochim. Biophys. Acta 24, 265–274 (1995).
D.S. Cassarino, J.K. Parks, W.D. ParkerJr, J.P. BennettJr. The parkinsonian neurotoxin MPP+ opens the mitochondrial permeability transition pore and releases cytochrome c in isolated mitochondria via an oxidative mechanism. Biochim Biophys Acta 6, 49–62 (1999).
G. Kroemer & J.C. Reed Mitochondrial control of cell death. Nature Med 6, 513–519 (2000)
H. Zou, W.J. Henzel, X. Liu, A. Lutschg & X. Wang. Apaf-1, a human protein homologous to C. elegans CED-4, participates in cytochrome c-dependent activation of caspase-3. Cell 90, 405–413 (1997).
S.M. Srinivasula, M. Ahmad, T. Fernandes-Alnemri & E.S. Al-nemri. Autoactivation of procaspase-9 by Apaf-l-mediated oligomerization. Mol. Cell 1, 949–957. (1998)
P. Klevenyi, O. Andreassen, R.J. Ferrante, J.R. SchleicherJr, R.M. Friedlander et al. Transgenic mice expressing a dominant negative mutant interleukin-lbeta converting enzyme show resistance to MPTP neurotoxicity. Neuroreport 25, 635–638 (1999)
D.W. Nicholson. From bench to clinic with apoptosis-based therapeutic agents Nature 407 810 – 816 (2000).
H. Mochizuki, H. Hayakawa, M. Migita, M. Shibata, R. Tanaka et al. An AAV- derived Apaf-1 dominant negative inhibitor prevents MPTP toxicity as anti- apoptotic gene therapy for Parkinson’s disease. Proc. Natl. Acad. Sci. USA (2001) in press.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2002 Kluwer Academic / Plenum Publishers, New York
About this chapter
Cite this chapter
Mochizuki, H., Hayakawa, H., Migita, M., Shimada, T., Miura, M., Mizuno, Y. (2002). Anti-Apoptotic Therapy for Parkinson’s Disease: Overexpression of an APAF-1-Dominant-Negative Inhibitor Can Block MPTP Toxicity. In: Mizuno, Y., Fisher, A., Hanin, I. (eds) Mapping the Progress of Alzheimer’s and Parkinson’s Disease. Advances in Behavioral Biology, vol 51. Springer, Boston, MA. https://doi.org/10.1007/978-0-306-47593-1_80
Download citation
DOI: https://doi.org/10.1007/978-0-306-47593-1_80
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4757-0973-5
Online ISBN: 978-0-306-47593-1
eBook Packages: Springer Book Archive